News for Healthier Living
New Research from Children's Hospital of Philadelphia to Transform Standard of Care Across the Globe for Newly Diagnosed Children with B-cell Acute Lymphoblastic Leukemia
Researchers at Children's Hospital of Philadelphia (CHOP) and the Children's Oncology Group (COG) announced the results of a Phase 3 study that demonstrated adding the bi-specific T-cell engager, blinatumomab, to chemotherapy for newly diagnosed National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) pediatric patients significantly improves survival outcomes. The results were published today in the New England Journal of Medicine and will be presented during the plenary session at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego on December 8.
December 7, 2024
December 21 2024December 20 2024December 19 2024December 18 2024December 17 2024December 16 2024December 15 2024December 14 2024December 13 2024December 12 2024December 11 2024December 10 2024December 9 2024December 8 2024December 7 2024
|
|
|
|
|